Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000909830 | SCV001054655 | benign | Hereditary spastic paraplegia 54 | 2019-12-31 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001847110 | SCV002104612 | likely benign | Hereditary spastic paraplegia | 2021-10-05 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003438578 | SCV004164626 | likely benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | DDHD2: BP4, BS2 |
Ambry Genetics | RCV004028608 | SCV004853891 | uncertain significance | Inborn genetic diseases | 2021-07-09 | criteria provided, single submitter | clinical testing | The c.226G>T (p.G76C) alteration is located in exon 3 (coding exon 2) of the DDHD2 gene. This alteration results from a G to T substitution at nucleotide position 226, causing the glycine (G) at amino acid position 76 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV003438578 | SCV005223396 | likely benign | not provided | criteria provided, single submitter | not provided |